Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Raghinaru

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Diabetes Care|October 12, 2018
First Look at Control-IQ: A New-Generation Automated Insulin Delivery SystemSue Brown, Dan Raghinaru, Emma Emory, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 19, 2014
A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusionRaj K Maturi, Vincent Chen, Dan Raghinaru, et al.
Diabetes Technology & Therapeutics|January 12, 2022
Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Marissa Town, Dan Raghinaru, et al.
Diabetes Care|December 5, 2025
Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 AntibodiesRoy W Beck, Irl B Hirsch, Dan Raghinaru, et al.
Diabetes Care|April 24, 2014
Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend systemRoy W Beck, Dan Raghinaru, R Paul Wadwa, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 21, 2024
Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 DiabetesRoy W Beck, Carol J Levy, Yogish C Kudva, et al.
Diabetes Technology & Therapeutics|January 31, 2022
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 DiabetesCarol J Levy, Grenye O'Malley, Dan Raghinaru, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Diabetes Care|October 12, 2018
First Look at Control-IQ: A New-Generation Automated Insulin Delivery SystemSue Brown, Dan Raghinaru, Emma Emory, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 19, 2014
A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusionRaj K Maturi, Vincent Chen, Dan Raghinaru, et al.
Diabetes Technology & Therapeutics|January 12, 2022
Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Marissa Town, Dan Raghinaru, et al.
Diabetes Care|December 5, 2025
Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 AntibodiesRoy W Beck, Irl B Hirsch, Dan Raghinaru, et al.
Diabetes Care|April 24, 2014
Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend systemRoy W Beck, Dan Raghinaru, R Paul Wadwa, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 21, 2024
Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 DiabetesRoy W Beck, Carol J Levy, Yogish C Kudva, et al.
Diabetes Technology & Therapeutics|January 31, 2022
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 DiabetesCarol J Levy, Grenye O'Malley, Dan Raghinaru, et al.
Pageof 5